Analysen af alvorlige bivirkninger var normal i den overordnede gruppe af patienter, der var tilmeldt de kliniske undersøgelser af ropinirol.
The analysis of Serious Adverse Events (SAE) was unremarkable in the overall group of patients enrolled in the ropinirole clinical studies.